Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Revaxis
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Revaxis is a combined booster vaccine containing reduced doses of diphtheria toxoid, tetanus toxoid, and inactivated poliovirus (types 1, 2, and 3). Developed by Sanofi Pasteur, it is indicated for active immunization against diphtheria, tetanus, and poliomyelitis in individuals aged 6 years and older. The vaccine is formulated with aluminum hydroxide as an adjuvant to enhance the immune response. It is typically used as a booster dose in individuals who have previously received a primary vaccination series, providing a convenient single-injection option to maintain protection against these three diseases. The reduced antigen content is specifically designed for booster use to minimize local reactions while maintaining effective seroprotection.
- Brand names
- Revaxis
- Other names
- Td-IPVTd-IPV vaccine
02
Targets
γδ TCR (T-cell receptor)BCR (Immunoglobulin G B Cell Receptor)PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on Revaxis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Revaxis.